Daiichi Sankyo Streamlines Corporate, R&D Organizations

TOKYO - As part of the process of giving the finishing touches on the merger of the former Daiichi and Sankyo pharmaceutical companies, Daiichi Sankyo, the second-largest Japanese pharmaceutical firm, will revamp its corporate and research and development divisions, effective April 1, the company announced Feb. 22. The reorganization in part is aimed at boosting its global presence by proactively mobilizing Indian subsidiary Ranbaxy resources, a company spokesman explained Feb. 23